SCY-770 Phase 1 Shows Favorable Safety, Phase 2 in ADPKD Set for Q4
SCYX sits 47% above its 52-week low of $3.53.
Summary
SCYNEXIS reported Phase 1 results for SCY-770, its oral direct AMPK activator for ADPKD. The drug was well tolerated with a favorable safety profile at higher doses. Phase 2 is on track to start in Q4 2026. This is the first clinical data for SCY-770 and supports advancement into a larger efficacy study. The company recently secured a $214M BARDA contract for SCY-247, strengthening its cash position into 2029.
At the time of this announcement, SCYX was trading at $5.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50M. The 52-week trading range was $3.53 to $9.12. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.